WCN26-7938 THE PREVALENCE OF MAGNESIUM SUPPLEMENTATION IN PATIENTS RECEIVING CISPLATIN: A SINGLE-CENTER STUDY IN JAPAN

Read full text Summarise with VIRAT
Authors: Naoko Katahashi, Takamasa Iwakura, Tatsuya Yagi, Hideo Yasuda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In Japan, the 2016 Clinical Practice Guideline for the Management of Renal Injury during Cancer Chemotherapy weakly recommended magnesium (Mg) supplementation to prevent cisplatin (CDDP)–induced acute kidney injury (AKI). However, the extent of its real-world implementation has not been well investigated, and CDDP-induced AKI continues to occur in patients without Mg supplementation. This study aimed to clarify the current status and temporal trends of Mg supplementation in patients receiving CDDP at Hamamatsu University Hospital and to identify issues related to its implementation.

Fields of Study & Subjects

Chemotherapy-induced organ toxicity mitigation Acute Kidney Injury Research Magnesium in Health and Disease

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104172–104172
Publication date
25 March 2026
Language
EN